Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Homocysteine studies collaboration. homocysteine and risk of ischaemic heart disease and stroke. a meta-analysis.
JAMA, 288 (2002), pp. 2015-2022
[2.]
D.S. Wald, M. Law, J.K. Morris.
Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis.
BMJ, 325 (2002), pp. 1202-1206
[3.]
C. Fernández-Miranda, M. Paz, J.L. Aranda, V. Néñez, P. Gómez, P. Díaz-Rubio, et al.
Homocisteína y progresión de la aterosclerosis de la arteria carótida en pacientes con enfermedad coronaria.
Med Clin (Barc), 121 (2003), pp. 561-564
[4.]
L.A. Kluijtmans, I.S. Young, C.A. Boreham, L. Murray, D. McMaster, H. McNulty, et al.
Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults.
Blood, 101 (2003), pp. 2483-2488
[5.]
A. De Bree, W.M. Verschuren, A.L. Bjorke-Monsen, N.M. Van der Put, S.G. Heil, F.J. Trijbels, et al.
Effect of the methylenetetrahydrofolate reductase 677 ? t mutation on the relations among folate intake and plasma folate and homocysteine concentrations in a general population sample.
Am J Clin Nutr, 77 (2003), pp. 687-993
[6.]
M. González-Gross, R. Sola, M.J. Castillo.
Folato: una vitamina en constante evolución.
Med Clin (Barc), 119 (2002), pp. 627-635
[7.]
M.C. Verhaar, E. Stroes, T.J. Rabelink.
Folates and cardiovascular disease.
Arterioscl Thromb Vasc Biol, 22 (2002), pp. 6-13
[8.]
V. Schachinger, M.B. Britten, A.M. Zeiher.
Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease.
Circulation, 101 (2000), pp. 1899-1906
[9.]
L. Calpe-Berdiel, J.C. Escolà-Gil, V. Ribas, R. Arcelus, F. Blanco-Vaca.
Caracterización de un modelo murino en el que la deficiencia parcial de folato no induce hiperhomocisteinemia.
Clin Invest Arteriosclerosis, 16 (2004), pp. 192-197
[10.]
D. Sun, A. Wollin, A.M. Stephen.
Moderate folate deficiency influences polyamine synthesis in rats.
J Nutr, 132 (2002), pp. 2632-2637
[11.]
A.G. Bostom, J. Selhub, P.F. Jacques, I.H. Rosenberg.
Power shortage: clinical trials testing the “homocysteine hypothesis” against a background of folic acid-fortified cereal grain flour.
Ann Intern Med, 135 (2001), pp. 133-137
[12.]
Homocysteine lowering trialists’ collaboration. lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials.
BMJ, 316 (1998), pp. 894-898
[13.]
D.S. Wald, L. Bishop, N.J. Wald, M.R. Law, E. Hennessy, J. McPartlin, et al.
Randomised trial of folic acid supplementation on serum homocysteine levels.
Arch Intern Med, 161 (2001), pp. 695-700
[14.]
A.S. De Vriese, F. Verbeke, B.F. Schrijvers, N.H. Lameire.
Is folate a promising agent in the prevention and treatment of cardiovascular disease in patients with renal failure?.
Kidney Int, 61 (2002), pp. 1199-1209
[15.]
D.G. Hackam, J.C. Peterson, J.D. Spence.
What level of plasma homocyst(e)ine should be treated? Effects of vitamin therapy on progression of carotid atherosclerosis in patients with homocyst(e)ine levels above and below 14 µmol/l.
Am J Hypertens, 13 (2000), pp. 105-110
[16.]
G. Schnyder, M. Roffi, R. Pin, Y. Flammer, H. Lange, F.R. Eberli, et al.
Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.
N Engl J Med, 345 (2001), pp. 1593-1600
[17.]
J.F. Toole, M.R. Malinow, L.E. Chambless, J.D. Spence, L.C. Pettigrew, V.J. Howard, et al.
Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death. the vitamin intervention for stroke prevention (VISP) randomized controlled trial.
JAMA, 291 (2004), pp. 656-675
Copyright © 2003. Sociedad Española de Arteriosclerosis y Elsevier España, S.L.